Valbiotis S.A.
ALVAL.PA · PAR
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.03 | -0.02 | 0.09 |
| FCF Yield | -24.75% | -38.54% | -2.69% | -11.95% |
| EV / EBITDA | -2.85 | -0.88 | -9.34 | -28.02 |
| Quality | ||||
| ROIC | -41.51% | -16.04% | -20.08% | -9.82% |
| Gross Margin | -1,017.86% | -2,642.86% | 312.13% | 100.00% |
| Cash Conversion Ratio | 0.85 | 0.89 | 1.64 | 0.31 |
| Growth | ||||
| Revenue 3-Year CAGR | -89.32% | 7.13% | 138.00% | 198.53% |
| Free Cash Flow Growth | -2.71% | -242.89% | 73.74% | -80.44% |
| Safety | ||||
| Net Debt / EBITDA | 0.93 | 4.38 | 3.82 | 4.22 |
| Interest Coverage | -34.53 | -132.50 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.75 | 0.56 | 2.05 | 0.00 |
| Cash Conversion Cycle | 1,643.82 | 4,299.23 | -397.79 | 90.21 |